Analysis
Simile, a startup building AI-simulated users, closed a $200 million Series B at a $2 billion valuation just five months after announcing a $100 million Series A. The round was led by Greenoaks, with participation from Index Ventures, Hanabi, Bain Capital Ventures, A*, Factory, Definition and CVS Health Ventures.
The company's product simulates human behavior at scale, letting enterprises test marketing campaigns, product changes and research questions against synthetic populations before spending on real-world testing. Its models already predict behavior for CVS Health, Wealthfront, Deloitte and Gallup. Founder Joon Sung Park's Stanford PhD research produced 'Smallville,' a project in which AI agents lived out simulated daily lives -- work that is the direct intellectual root of Simile's commercial platform.
“Revenue has grown fivefold since the company's February 2026 launch and headcount has passed 50 employees globally.”
The pace of the round -- a 20x valuation jump in five months -- is extreme even by 2026's standards, and puts Simile alongside a small cohort of AI-native startups minting unicorn-plus valuations within a year of launch. Revenue has grown fivefold since the company's February 2026 launch and headcount has passed 50 employees globally.
For GPs, Simile is a live test of whether 'synthetic user research' becomes a durable enterprise category or a feature eventually absorbed into existing research and analytics platforms from incumbents like Qualtrics or Gallup itself -- notably now also a Simile customer. The bear case is straightforward: synthetic simulations are only as good as the training data and assumptions behind them, and any high-profile miss between simulated and real-world behavior could quickly puncture enterprise trust in the category. What to watch: whether Simile's next round, if it comes this fast again, shows revenue keeping pace with valuation, and whether incumbents like Qualtrics respond by acquiring rather than competing.
